Dr. Angeleen Fleming

Biography

Angeleen Fleming obtained her PhD from University College London at the Great Ormond Street Institute of Child Health and has amassed around 20 years of experience in academia and biotech. Since 2009, she has been leading a zebrafish research group at the University of Cambridge, focusing on developing and utilizing zebrafish transgenic models to study neurodegenerative diseases and understand the underlying mechanisms of neurodegeneration. Her work emphasizes the importance of autophagy and protein clearance pathways, both in normal physiological and pathological conditions, highlighting features of late-onset neurodegenerative diseases, known as proteinopathies. These diseases include Alzheimer’s disease, Parkinson’s disease, tauopathies, and Huntington’s disease. Fleming's laboratory aims to identify genetic modifiers that influence disease severity and novel therapeutic compounds to mitigate the effects of such neurodegenerative conditions. Additionally, she has developed and characterized 11 zebrafish transgenic models dedicated to elucidating the causes of neurodegeneration and therapeutic mechanisms. The lab's innovative approaches include using photoconvertible proteins to investigate clearance processes of aggregate-prone proteins within neurons in vivo.

Research Interests